Schizophrenia

CE / CME

Incorporating Novel Treatment Options Into Schizophrenia Management

Nurses: 1.00 Nursing contact hour, including 1.00 hour of pharmacotherapy credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Social Workers: 1.00 ASWB ACE CE Credit

Psychologists: 1.00 APA CE Credit

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: June 13, 2023

Expiration: June 12, 2024

Jonathan M. Meyer
Jonathan M. Meyer, MD, DLFAPA

Pretest

Progress
1 2
Course Completed
1.

Which of the following is true regarding the efficacy and safety profiles of olanzapine/samidorphan and olanzapine?

2.

Emerging agents in the treatment of schizophrenia (TAAR1 agonists, muscarinic M1/M4 agonists, PAMs) decrease presynaptic dopamine release in striatal areas associated with psychosis. What is the clinical relevance of these novel mechanisms?

3.

You have a patient who responded to oral risperidone 5 mg/day in the past but is not willing to take oral medications now. He says that coming into the clinic is a burden for him. Which of the following would be the most appropriate treatment option for this patient?